Altogether, our findings suggest that the direct targeting of PTX3 or TLR4 may represent a promising novel therapeutic approach for the treatment of TNBC as well as other tumor types where TLR4 signaling activation strictly depends on PTX3 expression. Here, TLR4 is linked to neoplasm.